romiplostim (AMG531, Nplate)
Jump to navigation
Jump to search
Indications
- chronic immune thrombocytopenic purpura
Dosage
1-7 ug/kg SQ weekly
Adverse effects
- does not appear to increase the risk of progression from myelodysplastic syndrome to acute myeloid leukemia[3]
Mechanism of action
- small peptide that activates the megakaryocyte thrombopoietin receptor & stimulates platelet production
More general terms
References
- ↑ Kuter DJ et al, Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008, 371:395 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18242413
- ↑ Kuter DJ et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010 Nov 11; 363:1889. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21067381
George JN. Management of immune thrombocytopenia - Something old, something new. N Engl J Med 2010 Nov 11; 363:1959. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21067388 - ↑ 3.0 3.1 Boggs W Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes Medscape - Feb 01, 2018 https://www.medscape.com/viewarticle/892138